Pyxis Oncology (PYXS) Non-Current Deferred Tax Liability (2022 - 2024)

Pyxis Oncology (PYXS) has 3 years of Non-Current Deferred Tax Liability data on file, last reported at $2.2 million in Q3 2024.

• Non-Current Deferred Tax Liability for Q3 2024 came in at $2.2 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2024 was $2.2 million (changed N/A YoY), and the FY2023 annual result was $2.2 million, down 41.1% from the prior year.
• Non-Current Deferred Tax Liability was little changed at $2.2 million in Q3 2024 per PYXS's latest filing, from $2.2 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $3.7 million in Q4 2022 and troughed at $2.2 million in Q4 2023.
• A 3-year average of $2.5 million and a median of $2.2 million in 2023 frame the typical range for Non-Current Deferred Tax Liability.
• On a YoY basis, Non-Current Deferred Tax Liability climbed as much as 41.1% in 2023 and fell as far as 41.1% in 2023.
• A 3-year view of Non-Current Deferred Tax Liability shows it stood at $3.7 million in 2022, then sank by 41.1% to $2.2 million in 2023, then changed by 0.0% to $2.2 million in 2024.
• Business Quant data shows PYXS's Non-Current Deferred Tax Liability at $2.2 million in Q3 2024, $2.2 million in Q2 2024, and $2.2 million in Q1 2024.